0 CHECKOUT

Lung Transplantation - Pipeline Review, H1 2015

  • ID: 3330523
  • June 2015
  • 47 pages
  • Global Markets Direct
1 of 4

Lung Transplantation - Pipeline Review, H1 2015

Summary

This, ‘Lung Transplantation - Pipeline Review, H1 2015’, provides an overview of the Lung Transplantation’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Lung Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lung Transplantation and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation READ MORE >

Note: Product cover images may vary from those shown
2 of 4

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Lung Transplantation Overview
Therapeutics Development
Pipeline Products for Lung Transplantation - Overview
Pipeline Products for Lung Transplantation - Comparative Analysis
Lung Transplantation - Therapeutics under Development by Companies
Lung Transplantation - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Lung Transplantation - Products under Development by Companies
Lung Transplantation - Companies Involved in Therapeutics Development
Kamada Ltd.
Proteo, Inc.
Quark Pharmaceuticals, Inc.
Lung Transplantation - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
alpha-1 proteinase inhibitor (human) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Elafin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FX-06 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
R-503 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
R-801 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Human Follistatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RNAi Oligonucleotide for Lung Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lung Transplantation - Recent Pipeline Updates
Lung Transplantation - Dormant Projects
Lung Transplantation - Product Development Milestones
Featured News & Press Releases
Mar 12, 2015: Elafin combined with cyclosporine promises to overcome limitations of cyclosporine for preventing irreversible damage to transplanted organs
Dec 06, 2011: Proteo And Its Subsidiary Announce Major Advances In Elafin Development Program
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Lung Transplantation, H1 2015
Number of Products under Development for Lung Transplantation - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Lung Transplantation - Pipeline by Kamada Ltd., H1 2015
Lung Transplantation - Pipeline by Proteo, Inc., H1 2015
Lung Transplantation - Pipeline by Quark Pharmaceuticals, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Lung Transplantation Therapeutics - Recent Pipeline Updates, H1 2015
Lung Transplantation - Dormant Projects, H1 2015

List of Figures
Number of Products under Development for Lung Transplantation, H1 2015
Number of Products under Development for Lung Transplantation - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

Kamada Ltd.
Proteo, Inc.
Quark Pharmaceuticals, Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Cache

Our Clients

  • Merck & Co., Inc.
  • Celgene Corporation
  • GlaxoSmithKline PLC
  • Genentech, Inc.
  • Johnson & Johnson Services, Inc.
  • ViiV Healthcare